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Abstract 
 
Recent policy developments in the U.K. health system such as the Cancer Drugs Fund 
constitute a dangerous move away from evidence-based and ethically sound policy-
making, towards populist approaches that could ultimately damage public health. We 
argue that key players in the NHS such as National Institute of Health and Care 
Excellence (NICE) need to demonstrate leadership by reaffirming the underlying 
principles of the NHS and clearly communicating how the values and principles 
underpinning their methods are a pre-requisite for an efficient fair and sustainable 
NHS.   
(85 words) 
 3 
In a recent editorial, the Lancet argues that health deserves a “central role in the (UK) 
election campaign” and warns that the electorate “will not be satisfied with tired and 
politically reflexive solutions that betray the intellectual underinvestment in health by 
recent parliaments”.1 We could not agree more. Recent developments like the Cancer 
Drugs Fund (CDF)2 amount to a dangerous move away from health policy that is 
based on robust evidence and sound ethical principles, and writ-large pose a real 
threat to the future of the National Health Service (NHS). 
 
Policies like the CDF have emerged mostly due to political expediency and are now 
advocated by both main parties. However, key players within the NHS could be 
considered partly responsible because they have failed to adequately communicate 
their worth to the wider public. The National Institute of Health and Care Excellence 
(NICE) is one such case. Although aspects of NICE’s work can and should be 
improved, we argue that the Institute’s overall approach to evaluating new health 
technologies for use within the NHS is ethically sound. Yet NICE has struggled to 
communicate its values and procedures to the wider public, and it has thereby left the 
electorate unable to recognize when the health service is being used as a political 
battleground. We therefore urge NICE to use its central position within the NHS and 
in the public eye to inform the ensuing health debate by clarifying its values, as well 
as asserting their essential role for preserving a sustainable and fair NHS.  
 
The reasonableness of NICE 
 
A key function of NICE is to evaluate whether new health technologies offer “value 
for money” within the NHS. The Institute has developed its methods for making these 
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evaluations for more than 15 years. Today, NICE’s methodology is best described as 
“filtering” new technologies based on their cost-effectiveness.3 NICE uses Quality-
adjusted Life Years (QALYs) as a measure to judge the effectiveness of new 
technologies. It then evaluates how their cost-effectiveness compares to the cost-
effectiveness of existing interventions, and generally recommends funding new 
technologies that do not add costs beyond  £20,000–30,000 per QALY gained. 
Costlier technologies may still be funded, but this must be justified based on 
recognized social or ethical values—such as extending the end of life, addressing the 
needs of disabled people, relieving stigma, or reducing health inequalities (table).4, 5  
Thus, NICE’s methodology defaults to prioritizing the value of cost-effectiveness, but 
recognises that other values can overturn this default and “trump” the value of cost-
effectiveness. 
 
Table. NICE’s methodology for evaluating health interventions: values that can 
or cannot trump the value of cost-effectiveness. Based on NICE’s Social Value 
Judgments and Guide to the Methods of Technology Appraisal. 4, 6 Other social values 
that have been invoked in actual NICE appraisals are not represented.  
  
Recognized values or criteria Excluded values or criteria 
 Innovation not adequately captured in 
the measurement of health gain 
 Special consideration of the needs of 
disabled people 
 Special consideration of the relief of 
stigma 
 Special consideration of life-extending 
treatment at the end of life* 
 Individual choice or individuals’ 
values, cultural attitudes and religious 
views (if they support interventions 
that are not clinically effective and / or 
cost-effective) 
 Treating rare diseases or conditions as 
special 
 “Rule of rescue” 
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 Reducing health inequalities  Personal responsibility for health  
(unless a proxy for clinical 
effectiveness) 
 Race / ethnicity (unless a proxy for 
clinical effectiveness) 
 Age as a proxy for social worth% 
 Sex / gender and sexual orientation 
(unless a proxy for clinical 
effectiveness) 
 Socio-economic status and social roles 
* End-of-life criteria: 1) patients with life expectancy of <24 months, 2) intervention 
offers life extension of >3 months compared to existing alternatives, 3) intervention is 
licensed for small patient populations (total <7000 patients) 
 
 % Age may be invoked if 1) a good indicator of patients’ health status and / or 
likelihood of adverse effects and / or treatment response and 2) no practical way of 
identifying patients other than by age. Furthermore, a lower discount rate for costs 
and benefits may be applied if a treatment 1) restores full or near full health in 
patients who would otherwise die or have a very severely impaired life and 2) the 
resulting health benefits are long-term (>30 years, i.e. typically applying to younger 
patients).  
 
So understood, NICE’s method is eminently reasonable.3 Funded by general taxation, 
the NHS operates with a fixed budget that is insufficient to cover all conceivable and 
technically possible health needs. This implies that money spent on one set of 
interventions will inevitably displace resources devoted to other interventions. In a 
situation like this, there is a genuine risk of unfairness because the demands of the 
most vocal can easily drive out the claims of the needy. Allocating the NHS budget 
therefore requires an ethics of opportunity costs—and NICE’s methodology provides 
just that.  
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NICE’s methodology prioritizes the value of cost-effectiveness and thereby helps to 
ensure that the available resources for health and health care are used prudently. 
Moreover, it sets a general cost-effectiveness threshold for all services within the 
NHS. This does not only provide a rough and ready test of whether financing care for 
one group of patients is likely to lead to care for other patients being denied or 
delayed. It also embodies the idea that, prima facie, all patients have an equal claim to 
the available resources. Finally, the Institute’s methodology offers a framework for 
judging whether other recognized social and ethical values warrant funding 
technologies above the general cost-effectiveness threshold—or, put differently, 
whether other values justify the opportunity costs of financing costly interventions. 
This recognizes that patients can have justice claims to the available resources for 
health and health care over and above cost-effectiveness.  
 
The need for better communication 
 
While it is relatively straightforward to reconstruct and defend NICE’s methodology 
along the above lines, the Institute itself has failed to clearly communicate all the 
values that it serves. Its Guide to the Methods of Technology Appraisal focuses 
primarily on the criteria and procedures for evaluating evidence.6 The Social Value 
Judgements document—largely unknown beyond specialist confines—promises to set 
out NICE’s key principles, but does not deliver in this respect.4 It embraces a mixture 
of ethical theories and principles, legal obligations, recommendations from NICE’s 
Citizen’s Council, procedural ideals, institutional directives, and specific decision 
criteria and values. What is lacking is the overarching framework to unify these 
considerations.  
 7 
 
After more than a decade of its existence—a very long time in today’s NHS—there is 
still confusion and unhelpful controversy around NICE’s fundamental values. For 
example, some commentators often gloss the Institute’s methodology as simply an 
explicit or implicit attempt to maximize QALY gain within the NHS.7, 8, 9  For some 
economists, this is a virtue because they see a maximizing approach as a way of using 
available resources to best effect.7, 9 However, NICE’s methodology is clearly not one 
of simple maximization. If the Institute was trying to maximize benefit within the 
NHS, it would rank-order all interventions by their cost-effectiveness and recommend 
spending money only on items high up the list. The reality is very different, both 
because NICE endorses a satisficing approach rather than maximizing one, and 
because it recognises a range of other values that can trump the value of cost-
effectiveness. These distinctions are important. For if NICE did adopt a simple 
maximizing approach, then it would be open to numerous criticisms—for example, 
that its methodology systematically sacrifices important needs of small groups for the 
greater good. NICE’s failure to clarify its values thus leads to inaccurate glosses and 
controversy that is both polarising and unnecessary. 
 
Furthermore, given the Institute’s failure to adequately communicate its values, the 
electorate lacks a clear framework by which to evaluate recent policies like the CDF. 
If NICE conveyed its methodology and the underlying rationale more clearly, more 
people would be asking more questions about the opportunity costs of funding cancer 
drugs that have not (yet) been recommended by NICE; what—if anything—might 
justify special health expenditures for cancer; why legislators assumed that NICE's 
methodology did not account for the value we attach to cancer drugs, or could not be 
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modified in this respect; and so on. In other words, more clarity about NICE’s values 
and methods should help to press greater public accountability by politicians and 
legislators. 
 
Finally, NICE’s ambiguity about its methodology means that stakeholders and the 
wider public lack a clear framework for discussing how we should build on the 
Institute’s work in the pursuit of a just allocation of limited health care resources. 
Although we have argued that NICE’s overall methodology is reasonable, many 
details require further discussion. In particular, is the cost-effectiveness threshold of 
£20,000–30,000 per QALY set at the right level? Are all of the social and ethical 
values other than cost-effectiveness justified? Should NICE recognize additional 
values? How should competing values be balanced? By clarifying its present values 
and methods for evaluating new technologies, NICE would be able to respond better 
to critics from new quarters10, 11 while also providing a structure for constructive 
debate.  
 
The future of NICE 
 
We have argued that NICE’s overall methodology is eminently reasonable and 
requires, above all, better explanation. Ironically, the solution is already in NICE’s 
hands in its current revision of the Social Value Judgements (SVJ) document.12 NICE 
should seize the opportunity of re-drafting SVJ to elevate this document to the 
Institute’s principal statement of its overarching philosophy and values. NICE should 
also aim to clarify its values and publicise SVJ widely. Next, the SVJ document 
should be used to guide discussions both about NICE’s current methods and how 
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these methods should be applied to its expanding remit for social care. We recognize 
that these discussions will be challenging. However, we firmly believe that a clear 
framework of values is essential for guiding NICE as well as the wider public—both 
in the present and into the future.  
 
Conclusion 
 
The future of the NHS depends on making decisions based on robust evidence and 
sound ethical principles, but recent developments like the CDF suggest that support of 
these ideas is waning among politicians and legislators. We have argued that key NHS 
players are partly at fault because they have failed to clearly emphasise the values that 
must guide a fair and sustainable health service. NICE is a case point, in that it is not 
the Institute’s values and methods, but their presentation that is the problem.  
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